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Chronic Outpatient Sildenafil Therapy for Pulmonary Hypertension in a Child After
Cardiac Surgery
C.A. Knoderer , E.S. Ebenroth, and J.W. Brown
Abstract
We report the case of a 14-month-old male with d-transposition of the great arteries, ventricular septal
defect, and pulmonary hypertension successfully treated with long-term sildenafil following cardiac
surgery. To our knowledge, this is the first published report of long-term sildenafil treatment in a child
after corrective cardiac surgery.

Pulmonary hypertension associated with congenital heart disease in children remains a
significant cause of morbidity and mortality postoperatively [4, 8]. Despite many advances in the
treatment of adults with pulmonary hypertension, limited therapeutic options are available for
infants and children. Inhaled nitric oxide, which is a selective pulmonary vasodilator, has been
shown to be safe and effective in reducing pulmonary hypertension when used postoperatively in
pediatric cardiac surgery cases [6, 7]. Pharmacologic agents such as intravenous prostacyclin and
endothelin antagonists are options for the treatment of pulmonary hypertension; however,
inhaled nitric oxide remains the standard drug therapy at our institution. Intravenous
chlorpromazine has commonly been used as adjunctive therapy for pulmonary hypertension at
our institution due to its alpha-blocking and sedating effects. Sildenafil citrate is an oral
phosphodiesterase inhibitor that causes pulmonary vasodilation with minimal systemic
vasodilator effects [9]. Results from a number of small studies and case reports indicate that
sildenafil is safe and effective for pulmonary hypertension in the pediatric population. [1–3, 5,
10].
Case Report
A 14-month-old boy from the Phillipines arrived in the United States for adoption and was
admitted to the hospital with cyanosis and failure to thrive. Echocardiographic evaluation
revealed d-transposition of the great arteries, a large muscular ventricular septal defect (VSD), a
small secundum atrial septal defect (ASD), and evidence of elevated pulmonary artery pressures.
The patient underwent a preoperative cardiac catheterization to better assess pulmonary artery
pressures. Catheterization results (Table 1) indicated pulmonary hypertension and mildly
reactive pulmonary artery pressures. Despite these discouraging numbers, the patient underwent
an arterial switch procedure with a VSD closure and primary closure of the ASD. The patient
was mechanically ventilated and maintained on inhaled nitric oxide, intravenous fentanyl,
nitroglycerin, and cisatracurium infusions and intermittent intravenous chlorpromazine
postoperatively for management of pulmonary hypertension. He was weaned off the
nitroglycerin infusion on postoperative day 1. On postoperative day 2 he had a drop in heart rate
along with a decline in systemic blood pressures. Pulmonary artery pressures remained elevated
at approximately one-half systemic blood pressures, despite treatment with nitric oxide at 30
ppm. Nitric oxide was subsequently weaned off by postoperative day 5, at which time sildenafil
was initiated at 1 mg via the nasogastric tube every 6 hours (∼0.25 mg/kg/dose). The pulmonary
artery catheter was removed on postoperative day 6. Available hemodynamic data before and
after the initiation of sildenafil are summarized in Table 2.

Table 1
Preoperative cardiac catheterization results
Baseline 90% FiO2 90% FiO2 +NO 20 ppm
Q p/Q s 2

2.64

2.71

Rp

2.9

2.9

2.8

Rs

10.8

14.1

12.4

R p/R s 0.27

0.21

0.23

NO, nitric oxide; ppm, parts per million; Q p/Q s, pulmonary-to-systemic blood flow ratio; R p, pulmonary vascular resistance; R
s, systemic vascular resistance; R p/R s, ratio of pulmonary to systemic vascular resistance.
Table 2
Hemodynamic data before and after sildenafil dosing
Pulmonary artery pressures

Systemic blood pressures

Dose
No.

1-hr
predose

0.5-hr
postdose

1-hr
postdose

2-hr
postdose

1-hr
predose

0.5-hr
postdose

1-hr
postdose

2-hr
postdose

1

36/6

28/7

27/7

29/8

75/52

72/47

66/39

72/52

2

30/8

24/6

28/7

35/9

73/52

69/46

74/47

74/47

3

44/11

35/13

31/9

38/11

76/49

82/53

73/51

76/49

The patient was extubated on postoperative day 7 and discharged 13 days after surgery on a 2day weaning course of sildenafil. The sildenafil was initially weaned from 1 mg every 6 hours to
1 mg every 8 hours for 1 day while the patient remained in the hospital. The patient was then
discharged home on 1 mg every 12 hours for 1 day and then 1 mg every 24 hours for 1 day.
Additional medications upon discharge included furosemide and spironolactone. A follow-up
echocardiogram performed 2 days postdischarge revealed elevated pulmonary pressures with
pulmonary artery diastolic pressures estimated to be 30–40 mmHg. Sildenafil was restarted at 1
mg orally every 6 hours. Echocardiogram findings 2 months after surgery demonstrated
persistently elevated pulmonary pressures, with pulmonary artery diastolic pressures estimated to
be 25–30 mmHg. Sildenafil dosing was increased to 1 mg alternating with 2 mg every 6 hours
(∼0.25 mg/kg/dose alternating with ∼0.5 mg/kg/dose). A follow-up echocardiogram at 4 months
after surgery indicated normal pulmonary systolic and diastolic pressures, and no dosage
adjustments were made to the sildenafil. Sildenafil was increased to 2 mg orally every 6 hours
(∼0.25 mg/kg/dose) at a follow-up visit 7 months after surgery due to echocardiogram findings
suggestive of elevated right-sided pressures. Echocardiogram findings 9 months following
surgery demonstrated normal pulmonary pressures. Sildenafil was subsequently weaned off after
having completed 323 days of treatment. Sildenafil was weaned by changing to 2 mg every 12
hours for 2 weeks and then 2 mg every 24 hours for 2 weeks, after which the drug was
discontinued. A follow-up echocardiogram approximately 4 months after discontinuation of
sildenafil showed normal pulmonary artery pressures. No adverse effects were observed by the
cardiologist or reported by the parents during treatment course. For this patient, the
compounding pharmacy at our institution made 1-mg sildenafil capsules from the 25-mg

sildenafil tablets. The contents of the capsule were mixed with approximately 5–10 ml of water
immediately prior to the scheduled dose and administered to the child. The child remains healthy
at 3 years of age and does not require any cardiac medications.
Discussion
Sildenafil is a phosphodiesterase (PDE) inhibitor with high selectivity against isoform 5 [9].
Phosphodiesterase-5 (PDE-5) is predominantly found in smooth muscle cells of the corpora
cavernosa and in high concentrations in the pulmonary vasculature. The phosphodiesterase
enzymes catalyze the breakdown of cyclic nucleoside monophosphates. Isoform 5 is a cGMPspecific PDE [9]. Inhibition of PDE-5 results in an increased cellular level of cGMP, which
increases vascular smooth muscle relaxation [1, 9]. Due to the high concentration of PDE-5 in
the pulmonary vasculature, sildenafil use causes significant pulmonary blood pressure reduction
and may benefit certain patients with pulmonary hypertension [1, 9].
Randomized, placebo-controlled clinical trials evaluating the use of sildenafil in children with
pulmonary hypertension after cardiac surgery have not been published. However, there are many
case reports that illustrate its effectiveness as a pulmonary vasodilator and benefit for patients
with pulmonary hypertension. These reports all evaluate short-term treatment with sildenafil. In a
case series of 16 patients, oral sildenafil significantly reduced mean pulmonary artery pressure
from 50 ± 8 to 38 ± 12 mmHg during cardiac catheterization [5]. In 5 of the patients in this
series, sildenafil allowed for discontinuation of inhaled nitric oxide 4–6 hours after an oral
sildenafil dose [5]. Similar results were observed in a study evaluating intravenous sildenafil. In
children undergoing cardiac catheterization and following cardiac surgery, intravenous sildenafil
was found to be an effective pulmonary vasodilator [10]. Intravenous sildenafil caused a
significant decrease in pulmonary artery pressures in both study groups. It is important to note
that this was a European and Canadian study and that intravenous sildenafil is not yet available
in the United States.
Other reports have shown that oral sildenafil may aid in the successful withdrawal of nitric oxide
[2, 3]. Sildenafil initiation in a 9-month-old with congenital heart disease allowed the weaning of
nitric oxide while inducing no further pulmonary hypertensive episodes [2]. No rebound
pulmonary hypertension was observed in the 36 hours after the nitric oxide was discontinued.
Atz and Wessel [3] observed similar findings in three patients with pulmonary hypertension.
Sildenafil administration facilitated withdrawal of nitric oxide in these patients with no rebound
pulmonary hypertension observed. cGMP sampling in these patients showed increases in cGMP
plasma levels after sildenafil dosing.
Outpatient oral sildenafil therapy is described in a 4-year-old girl with pulmonary hypertension
[1]. Treatment was initiated in this patient with intravenous prostacyclin, which produced a 10%
decrease in pulmonary artery pressure but no increase in cardiac output. Oral sildenafil was
initiated, resulting in an average 10% increase in mixed venous oxygen saturation after drug
administration. An increase in exercise capacity was observed in a 3 -month follow-up visit in
this patient [1].

Sildenafil was initiated in our patient in the immediate postoperative period to facilitate
withdrawal of inhaled nitric oxide and prevent rebound pulmonary hypertension. Nitric oxide
was chosen initially after surgery due to the preoperative cardiac catheterization results along
with postoperative elevations in pulmonary artery pressures and echocardiogram findings
consistent with pulmonary hypertension. Outpatient therapy with sildenafil was continued
primarily due to echocardiogram findings suggestive of pulmonary hypertension. There are no
reports detailing the use of sildenafil for this duration in a child after corrective cardiac surgery.
A dose–time relationship was observed for the pulmonary artery pressure in our patient
immediately after sildenafil dosing. As seen in Table 2, the initial decreases in pulmonary arterial
pressures were seen in the first 30–60 minutes after dosing. The average decrease in systolic
pulmonary artery pressures from baseline to that observed 30 and 60 minutes after a sildenafil
dose were 21% and 27%, respectively (Table 2). Pulmonary pressures then began to rise
approximately 2 hours after dosing. Systemic blood pressures remained stable after sildenafil
dosing. Average decreases in systolic blood pressure were 4% and 8% 30 and 60 minutes after
dosing, respectively. The pulmonary artery catheter was removed soon after initiation of
sildenafil and a sustained effect on pulmonary artery pressures could not be observed in this
patient. An attempt to discontinue sildenafil therapy was made prior to patient discharge after
surgery. However, echocardiogram findings at the immediate follow-up visit were suggestive of
recurrent pulmonary hypertension. A series of echocardiogram results showed persistent
pulmonary hypertension. Of note was the 4-month postoperative echocardiogram that suggested
normal pulmonary pressures, whereas the 7-month postoperative echocardiogram revealed
elevated pressures. This result may be due to the 1.4-kg weight increase of the patient in this
time period and the overall decrease in the dose. Dosing was increased to 2 mg every 6 hours (∼
0.25 mg/kg/dose) and was similar to the dosing used initially after surgery. After dosing was
increased, pulmonary pressures gradually returned to normal.
This case illustrates the beneficial effects of sildenafil for patients with pulmonary hypertension
after cardiac surgery. In this patient, the resolution of pulmonary hypertension is thought to be
due to the combination of long-term sildenafil therapy and time after surgical repair of his
congenital heart defect. Although it is difficult to determine the extent of the effect of sildenafil,
echocardiogram findings corroborate that sildenafil was an effective treatment for pulmonary
hypertension in this patient. Sildenafil appears to be an effective pulmonary vasodilator, and in
clinical situations similar to the one presented in this report it should be considered as an option
for pulmonary hypertension. Randomized, placebo-controlled clinical studies are needed to
determine the effectiveness of long-term sildenafil therapy for patients with pulmonary
hypertension.
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